BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20663947)

  • 21. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.
    Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Steitz J; Roszkiewicz J; Bieber T; Tüting T
    Clin Exp Dermatol; 2005 Nov; 30(6):702-6. PubMed ID: 16197392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
    Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
    J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome.
    Scala E; Abeni D; Palazzo P; Liso M; Pomponi D; Lombardo G; Picchio MC; Narducci MG; Russo G; Mari A
    Int Arch Allergy Immunol; 2012; 157(2):159-67. PubMed ID: 21985996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD164 identifies CD4
    Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
    Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
    Stevens SR; Baron ED; Masten S; Cooper KD
    Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
    Introcaso CE; Hess SD; Kamoun M; Ubriani R; Gelfand JM; Rook AH
    J Am Acad Dermatol; 2005 Sep; 53(3):428-34. PubMed ID: 16112348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunophenotypic identification of Sezary cells in peripheral blood.
    Bogen SA; Pelley D; Charif M; McCusker M; Koh H; Foss F; Garifallou M; Arkin C; Zucker-Franklin D
    Am J Clin Pathol; 1996 Dec; 106(6):739-48. PubMed ID: 8980349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4 + /CD7- T cell frequency and polymerase chain reaction-based clonality assay correlate with stage in cutaneous T cell lymphomas.
    Laetsch B; Häffner AC; Döbbeling U; Seifert B; Ludwig E; Burg G; Dummer R
    J Invest Dermatol; 2000 Jan; 114(1):107-11. PubMed ID: 10620124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.
    Samimi S; Benoit B; Evans K; Wherry EJ; Showe L; Wysocka M; Rook AH
    Arch Dermatol; 2010 Dec; 146(12):1382-8. PubMed ID: 20713771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sézary syndrome originates from heavily mutated hematopoietic progenitors.
    Harro CM; Sprenger KB; Chaurio RA; Powers JJ; Innamarato P; Anadon CM; Zhang Y; Biswas S; Mandal G; Mine JA; Cortina C; Nagy MZ; Martin AL; Handley KF; Borjas GJ; Chen PL; Pinilla-Ibarz J; Sokol L; Yu X; Conejo-Garcia JR
    Blood Adv; 2023 Sep; 7(18):5586-5602. PubMed ID: 37531660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
    Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD7-positive Sézary syndrome with a Th1 cytokine profile.
    Yagi H; Tokura Y; Furukawa F; Takigawa M
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):368-74. PubMed ID: 8655729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
    Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
    Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome.
    Morice WG; Katzmann JA; Pittelkow MR; el-Azhary RA; Gibson LE; Hanson CA
    Am J Clin Pathol; 2006 Mar; 125(3):364-74. PubMed ID: 16613339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
    Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
    Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.
    Wysocka M; Kossenkov AV; Benoit BM; Troxel AB; Singer E; Schaffer A; Kim B; Dentchev T; Nagata S; Ise T; Showe LC; Rook AH
    J Invest Dermatol; 2014 Jan; 134(1):229-236. PubMed ID: 23792457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.